CVIA Journal

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Cardiac dysfunction is a prevalent and serious complication after cardiac arrest (CA), yet limited therapeutic interventions are available. Cyclic GMP-AMP synthase (cGAS), a critical mediator of innate immune responses, has recently been identified as a potential contributor to cardiac dysfunction. This study was aimed at investigating the role of cGAS in post-CA cardiac dysfunction.

In vivo, in rats with ventricular fibrillation (VF)-induced CA, a selective cGAS inhibitor (RU.521) was used to specifically inhibit cGAS activity, thereby blocking its downstream signaling pathway. In vitro, hypoxia and reoxygenation (H/R) were used to stimulate H9C2 cardiomyocytes, and a specific siRNA targeting cGAS was applied to knock down cGAS expression. (more…)